Eversana, an independent provider of commercial services to the life science industry, has reached a deal to acquire Burlington, Ontario-based Cornerstone Research Group Inc. The company is considered the leader in Health Economics and Outcomes Research services, working with leading pharmaceutical and medical device companies across the globe.
"Pharmaceutical companies face strong pressures to quickly assess and quantify both the direct and indirect value of their in-market products and development pipeline," Eversana CEO Jim Lang said in a statement. "By adding a strong health economics and outcomes capability to our integrated commercial platform, we can now conceptualize, deliver and measure value at every stage of the product lifecycle from clinical trials to ongoing patient adherence. The Cornerstone Research Group team brings tremendous expertise that will deliver immediate value to our clients worldwide, and we're thrilled to have them on board."
Cornerstone Research Group will transition to the Eversana brand in the coming quarter, and the company's partners, Chris Cameron, Daniel Grima and Melissa Thompson, will assume leadership roles at Eversana.
Financial details of the acquisition are not being disclosed.
